#Paris #France #Echosens #LiverHealth #Baujard

Echosens Welcomes Romain Baujard as Group Chief Executive Officer

Echosens, a leading global diagnostic company known for its non-invasive medical devices and services, has announced the appointment of Romain Baujard as its new Group Chief Executive Officer. Effective May 1, 2026, Baujard takes over from Dominique Legros, who is set to retire after a successful tenure that saw the company undergo significant global expansion.

A Strategic Shift in Leadership

This leadership transition marks a pivotal moment for Echosens as it aims to elevate liver health as an essential aspect of cardiometabolic care. Under Legros's stewardship, Echosens achieved notable advancements in the adoption of its innovative technologies, including FibroScan®, which have found their place not just in hepatology, but extending into areas like diabetology and endocrinology. Baujard's background positions him well to capitalize on these developments and drive future growth.

Romain Baujard’s Vision

Having joined Echosens in 2015, Baujard has held numerous strategic roles, most recently serving as Vice President of Pharma. His extensive experience encompasses global marketing and commercial operations that were pivotal in forging partnerships with significant pharmaceutical companies. In his new role, he expressed excitement about leading the next phase of growth for Echosens.

> "I am honored to take on this responsibility," said Baujard. "Echosens is at a key turning point as innovation accelerates across cardiometabolic care. Liver assessment is becoming essential to how patients are evaluated and managed. Our opportunity is to embed liver assessment as an integrated part of routine care at scale."

This statement not only reflects his vision but also points to the ongoing need for enhanced liver health awareness within the healthcare community. With the prevalence of metabolic diseases on the rise globally, healthcare providers seek out solutions that align with Echosens’ mission.

Collaborative Growth

Backed by substantial partnerships, including backing from Inner Mongolia FuRui Medical Science and Astorg, a pan-European private equity firm, Echosens plans to bolster its global platform. These collaborations will facilitate continued expansion in clinical settings, enabling enhanced detection, risk stratification, and management of liver health.

Baujard's leadership comes at a time when the need for non-invasive health assessments is more pertinent than ever. He plans to further leverage digital and AI-driven capabilities within Echosens' technologies, increasing access for clinicians and thus supporting better healthcare outcomes across a variety of fields.

A Look Back

Dominique Legros's legacy includes not only geographic expansion but reinforcing Echosens as a standard within non-invasive liver assessments. His leadership has resulted in substantial advancements in clinical adoption, which Baujard is now tasked with building upon. “Leading Echosens has been a privilege,” Legros said. “I am proud of what our teams have accomplished to bring liver health to the forefront of global care.” Legros's insights into the company's direction are a testament to the robust framework he has laid down, which Baujard will continue to nurture and evolve.

As Echosens embarks on this new chapter, the focus will remain firmly on making liver health a vital sign within cardiometabolic care, a mission strengthened under Baujard's leadership. As the company prepares for this transformative phase, stakeholders are optimistic about its future trajectory and the continued advancements in non-invasive health solutions, ensuring that liver health indeed matters in comprehensive patient evaluations.